{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T19:56:06Z","timestamp":1780343766807,"version":"3.54.1"},"reference-count":42,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,11,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Castleman disease (CD) describes a heterogeneous group of hematologic disorders that share characteristic lymph node histopathology. Patients of all ages present with either a solitary enlarged lymph node (unicentric CD) or multicentric lymphadenopathy (MCD) with systemic inflammation, cytopenias, and life-threatening multiple organ dysfunction resulting from a cytokine storm often driven by interleukin 6 (IL-6). Uncontrolled human herpesvirus-8 (HHV-8) infection causes approximately 50% of MCD cases, whereas the etiology is unknown in the remaining HHV-8-negative\/idiopathic MCD cases (iMCD). The limited understanding of etiology, cell types, and signaling pathways involved in iMCD has slowed development of treatments and contributed to historically poor patient outcomes. Here, recent progress for diagnosing iMCD, characterizing etio-pathogenesis, and advancing treatments are reviewed. Several clinicopathological analyses provided the evidence base for the first-ever diagnostic criteria and revealed distinct clinical subtypes: thrombocytopenia, anasarca, fever, reticulin fibrosis\/renal dysfunction, organomegaly (iMCD-TAFRO) or iMCD-not otherwise specified (iMCD-NOS), which are both observed all over the world. In 2014, the anti-IL-6 therapy siltuximab became the first iMCD treatment approved by the US Food and Drug Administration, on the basis of a 34% durable response rate; consensus guidelines recommend it as front-line therapy. Recent cytokine and proteomic profiling has revealed normal IL-6 levels in many patients with iMCD and potential alternative driver cytokines. Candidate novel genomic alterations, dysregulated cell types, and signaling pathways have also been identified as candidate therapeutic targets. RNA sequencing for viral transcripts did not reveal novel viruses, HHV-8, or other viruses pathologically associated with iMCD. Despite progress, iMCD remains poorly understood. Further efforts to elucidate etiology, pathogenesis, and treatment approaches, particularly for siltuximab-refractory patients, are needed.<\/jats:p>","DOI":"10.1182\/asheducation-2018.1.318","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T18:13:59Z","timestamp":1555438439000},"page":"318-325","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":14,"title":["Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease"],"prefix":"10.1182","volume":"2018","author":[{"given":"David C.","family":"Fajgenbaum","sequence":"first","affiliation":[{"name":"Division of Translational Medicine & Human Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"19","key":"2019111520592741400_B1","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1182\/blood-2013-12-545087","article-title":"HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy","volume":"123","author":"Fajgenbaum","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2019111520592741400_B2","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1016\/S2352-3026(16)00006-5","article-title":"Idiopathic multicentric Castleman\u2019s disease: a systematic literature review","volume":"3","author":"Liu","year":"2016","journal-title":"Lancet Haematol"},{"issue":"5","key":"2019111520592741400_B3","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.3109\/10428194.2014.953145","article-title":"Use of a claims database to characterize and estimate the incidence rate for Castleman disease","volume":"56","author":"Munshi","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2019111520592741400_B4","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/CCO.0b013e328355e0f3","article-title":"Recent advances in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease","volume":"24","author":"Uldrick","year":"2012","journal-title":"Curr Opin Oncol"},{"issue":"15","key":"2019111520592741400_B5","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1182\/blood-2016-10-747477","article-title":"Relapse of HHV8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients","volume":"129","author":"Pria","year":"2017","journal-title":"Blood"},{"issue":"11","key":"2019111520592741400_B6","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/ajh.23291","article-title":"The clinical spectrum of Castleman\u2019s disease","volume":"87","author":"Dispenzieri","year":"2012","journal-title":"Am J Hematol"},{"issue":"7","key":"2019111520592741400_B7","doi-asserted-by":"crossref","first-page":"64","DOI":"10.17116\/terarkh201587764-71","article-title":"Clinical and morphological features of different types of Castleman\u2019s disease [in Russian]","volume":"87","author":"Melikyan","year":"2015","journal-title":"Ter Arkh"},{"issue":"4","key":"2019111520592741400_B8","doi-asserted-by":"crossref","first-page":"253","DOI":"10.5045\/br.2014.49.4.253","article-title":"Clinical features and outcomes in patients with human immunodeficiency virus-negative, multicentric Castleman\u2019s disease: a single medical center experience","volume":"49","author":"Seo","year":"2014","journal-title":"Blood Res"},{"issue":"1","key":"2019111520592741400_B9","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/cas.13439","article-title":"Clinical characteristics and outcomes of Castleman disease: a multicenter study of 185 Chinese patients","volume":"109","author":"Zhang","year":"2018","journal-title":"Cancer Sci"},{"issue":"2","key":"2019111520592741400_B10","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/ajh.24242","article-title":"Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease","volume":"91","author":"Iwaki","year":"2016","journal-title":"Am J Hematol"},{"issue":"2","key":"2019111520592741400_B11","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/bjh.15019","article-title":"The full spectrum of Castleman disease: 273 patients studied over 20 years","volume":"180","author":"Oksenhendler","year":"2018","journal-title":"Br J Haematol"},{"issue":"12","key":"2019111520592741400_B12","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood-2016-11-748855","article-title":"Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease","volume":"129","author":"Yu","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2019111520592741400_B13","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2016-10-746933","article-title":"International, evidence-based consensus diagnostic criteria for HHV-8-negative\/idiopathic multicentric Castleman disease","volume":"129","author":"Fajgenbaum","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2019111520592741400_B14","doi-asserted-by":"crossref","first-page":"e01491","DOI":"10.1128\/mBio.01491-15","article-title":"Virome capture sequencing enables sensitive viral diagnosis and comprehensive virome analysis","volume":"6","author":"Briese","year":"2015","journal-title":"MBio"},{"issue":"suppl 1","key":"2019111520592741400_B15","article-title":"Virome capture sequencing in Castleman disease identifies associations with Herpesviridae family members but no novel viruses [abstract]","volume":"130","author":"Nabel","year":"2017","journal-title":"Blood"},{"issue":"7","key":"2019111520592741400_B16","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/rheumatology\/kep121","article-title":"The clinical spectrum of 94 patients carrying a single mutated MEFV allele","volume":"48","author":"Kon\u00e9-Paut","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"2019111520592741400_B17","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1056\/NEJMc1405506","article-title":"Mutant ADA2 in vasculopathies","volume":"371","author":"Van Eyck","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111520592741400_B18","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/modpathol.2013.202","article-title":"Monoclonality and cytogenetic abnormalities in hyaline vascular Castleman disease","volume":"27","author":"Chang","year":"2014","journal-title":"Mod Pathol"},{"issue":"2","key":"2019111520592741400_B19","first-page":"212","article-title":"Chromosomal abnormalities in Castleman\u2019s disease with high levels of serum interleukin-6 [in Japanese]","volume":"34","author":"Nakamura","year":"1993","journal-title":"Rinsho Ketsueki"},{"issue":"5","key":"2019111520592741400_B20","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/bloodadvances.2017009654","article-title":"Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas","volume":"2","author":"Nagy","year":"2018","journal-title":"Blood Adv"},{"issue":"19","key":"2019111520592741400_B21","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1158\/1078-0432.CCR-15-0134","article-title":"Analysis of inflammatory and anemia-related biomarkers in a randomized, double-blind, placebo-controlled study of siltuximab (anti-IL6 monoclonal antibody) in patients with multicentric Castleman disease","volume":"21","author":"Casper","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2019111520592741400_B22","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1182\/blood.V84.5.1434.1434","article-title":"Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study","volume":"84","author":"van Gameren","year":"1994","journal-title":"Blood"},{"issue":"8","key":"2019111520592741400_B23","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood-2004-12-4602","article-title":"Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease","volume":"106","author":"Nishimoto","year":"2005","journal-title":"Blood"},{"issue":"30","key":"2019111520592741400_B24","doi-asserted-by":"crossref","first-page":"30408","DOI":"10.18632\/oncotarget.4655","article-title":"A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease","volume":"6","author":"van Rhee","year":"2015","journal-title":"Oncotarget"},{"issue":"23","key":"2019111520592741400_B25","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1200\/JCO.2009.27.2377","article-title":"Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman\u2019s disease","volume":"28","author":"van Rhee","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111520592741400_B26","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S1470-2045(14)70319-5","article-title":"Siltuximab for multicentric Castleman\u2019s disease: a randomised, double-blind, placebo-controlled trial","volume":"15","author":"van Rhee","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"2019111520592741400_B27","doi-asserted-by":"crossref","first-page":"42316","DOI":"10.1038\/srep42316","article-title":"Elevated serum interferon \u03b3-induced protein 10 kDa is associated with TAFRO syndrome","volume":"7","author":"Iwaki","year":"2017","journal-title":"Sci Rep"},{"issue":"2","key":"2019111520592741400_B28","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1001\/jamadermatol.2013.1552","article-title":"Eruptive cherry hemangiomatosis associated with multicentric Castleman disease: a case report and diagnostic clue","volume":"149","author":"Fajgenbaum","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"7","key":"2019111520592741400_B29","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/ajh.25123","article-title":"Plasma proteomics identifies a \u2018chemokine storm\u2019 in idiopathic multicentric Castleman disease","volume":"93","author":"Pierson","year":"2018","journal-title":"Am J Hematol"},{"issue":"6","key":"2019111520592741400_B30","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1158\/1535-7163.MCT-10-0156","article-title":"Successful treatment of Castleman\u2019s disease with interleukin-1 receptor antagonist (Anakinra)","volume":"9","author":"El-Osta","year":"2010","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"2019111520592741400_B31","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/MPH.0b013e31818ab31f","article-title":"IL-1RA agonist (anakinra) in the treatment of multifocal Castleman disease: case report","volume":"30","author":"Galeotti","year":"2008","journal-title":"J Pediatr Hematol Oncol"},{"issue":"5","key":"2019111520592741400_B32","first-page":"404","article-title":"Expression of interleukin-6 and its clinicopathological significance in Castleman\u2019s disease [in Chinese]","volume":"34","author":"Lai","year":"2013","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"5","key":"2019111520592741400_B33","first-page":"474","article-title":"Diagnostic utility of interleukin-6 expression by immunohistochemistry in differentiating Castleman disease subtypes and reactive lymphadenopathies","volume":"46","author":"Post","year":"2016","journal-title":"Ann Clin Lab Sci"},{"issue":"11","key":"2019111520592741400_B34","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1097\/PAS.0b013e318264e223","article-title":"TdT+ T-lymphoblastic populations are increased in Castleman disease, in Castleman disease in association with follicular dendritic cell tumors, and in angioimmunoblastic T-cell lymphoma","volume":"36","author":"Ohgami","year":"2012","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"2019111520592741400_B35","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1365-2141.2006.06212.x","article-title":"Effects of bortezomib on pro-inflammatory cytokine levels and transfusion dependency in a patient with multicentric Castleman disease","volume":"134","author":"Hess","year":"2006","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111520592741400_B36","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1158\/1541-7786.MCR-10-0368","article-title":"Bortezomib induces nuclear translocation of I\u03baB\u03b1 resulting in gene-specific suppression of NF-\u03baB\u2013dependent transcription and induction of apoptosis in CTCL","volume":"9","author":"Juvekar","year":"2011","journal-title":"Mol Cancer Res"},{"issue":"1-3","key":"2019111520592741400_B37","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0171-2985(97)80035-6","article-title":"Interleukin-6 and CAAT\/enhancer binding protein beta-deficient mice act as tools to dissect the IL-6 signalling pathway and IL-6 regulation","volume":"198","author":"Alonzi","year":"1997","journal-title":"Immunobiology"},{"issue":"suppl 1","key":"2019111520592741400_B38","article-title":"Prolonged remission achieved in a relapsing idiopathic multicentric Castleman disease patient with a novel, targeted treatment approach [abstract]","volume":"130","author":"Fajgenbaum","year":"2017","journal-title":"Blood"},{"key":"2019111520592741400_B39","article-title":"International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease","author":"van Rhee","journal-title":"Blood"},{"key":"2019111520592741400_B40","article-title":"Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data","author":"Morra","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"2019111520592741400_B41","article-title":"Preliminary results from accelerate, an international, web-based, natural history registry of Castleman disease [abstract]","volume":"130","author":"Fajgenbaum","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2019111520592741400_B42","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1016\/S2352-3026(16)00007-7","article-title":"The collaborative network approach: a new framework to accelerate Castleman\u2019s disease and other rare disease research","volume":"3","author":"Fajgenbaum","year":"2016","journal-title":"Lancet Haematol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2018\/1\/318\/1251643\/hem01843.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2018\/1\/318\/1251643\/hem01843.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T23:40:56Z","timestamp":1573861256000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2018\/1\/318\/277567\/Novel-insights-and-therapeutic-approaches-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,30]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,11,30]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2018.1.318","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,30]]}}}